This article has not been copyedited and formatted. The final version may differ from this version. Bicifadine [(±)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane HCl; DOV 220,075, Figure 1 ] is an inhibitor of norepinephrine and serotonin uptake that is being developed for the treatment of acute and chronic pain. The compound is a non-narcotic analgesic (Epstein et al., 1982) that is active in preclinical models of neuropathic pain. In animals, bicifadine has been shown to inhibit dopamine uptake, thus making it a functional triple reuptake inhibitor with antinociceptive and anti-allodynic activity in acute, persistent, and chronic pain models (Basile et al., 2007) . Clinically, it has been shown to be effective in the treatment of acute dental (Stern et al., 2005) and bunionectomy pain (Riff et al., 2006) .
The metabolites of bicifadine formed by mouse, rat, monkey, and human hepatocytes and microsomes were reported previously (Erickson et al., 2007) .
The two main metabolic pathways in all 4 species were formation of a lactam and the oxidation of the tolylmethyl group. When tested in human in vitro systems, MAO-B was the principal enzyme that formed the lactam while CYP2D6 was responsible for the initial hydroxylation of the tolylmethyl group.
The present studies were performed to determine the pharmacokinetics, metabolism, and disposition of bicifadine in the mouse, rat, and monkey, the species used in toxicological and carcinogenicity studies.
This article has not been copyedited and formatted. The final version may differ from this version. mg/kg) dose and blood samples were collected under isoflurane anesthesia by cardiac puncture using tripotassium EDTA as the anticoagulant. Blood from 9 mice per time point was pooled to form 3 samples, with equal volumes from the 3 mice in each pool, in order to have sufficient sample for analyses. Brains were collected from rats that were euthanized on the first day after dosing and were rinsed with cold saline, blotted dry, weighed, and placed on dry ice before being stored at -80ºC. On the day before dosing, BDC rats were lightly anesthetized and the bile and duodenal cannulas were externalized. A solution of 4 mM sodium taurocholate in isotonic saline was infused into the duodenal cannula at a rate of 0.9 ml/h; the infusion continued until the time of sacrifice. Samples were collected for 72 h after dosing. Monkeys (3/sex) were dosed by i.v. bolus at 4 mg/kg via a saphenous vein and blood samples were collected from a femoral vein. Six weeks later, the monkeys were dosed orally by gavage at 8 mg/kg and blood samples were collected. Urine and feces were collected for 168 h from mice (3/cage), rats, and monkeys that were housed in metabolism cages; cages were rinsed at least every 24 h and wiped at the end of the collection period.
Radioactivity Analysis. Blood and plasma samples (0.1 ml), urine samples (0.2 g), and cage rinses (0.5 g) were added to Ultima Gold XR scintillation cocktail. Feces were homogenized in water and samples (0.2 g) were combusted using a Packard Model 307 Sample Oxidizer (PerkinElmer Life and Analytical Sciences). Cage wipes were extracted in water using gentle shaking and samples (0.5 g) were added to the scintillation fluid. The pooled mouse carcasses (3/sample) were cut into pieces and digested using 1 N NaOH and was added to each tube, the tubes were shaken for 15 min, and centrifuged. The organic layer was evaporated to dryness and 1 ml of diethyl ether was added.
The tubes were mixed by vortexing and the samples were dried under a stream of nitrogen. The samples were reconstituted in 200 µl of methanol and transferred to autosampler vials. The extracts were injected onto a Hypersil C18-BDS column (50 x 4.6 mm, 3 µm particle size) with a C18 guard column (Agilent Technology, Santa Clara, CA). The mobile phase was 30% acetonitrile/35% methanol/0.5% formic acid/34.5% 5 mM ammonium acetate (v/v/v/v) with a flow rate of 0.4 ml/min. The mass spectrometry was done using a Micromass Quattro respectively; the cone and desolvation gas flows were approximately 100 l and 700 l N 2 /h, respectively. The collision gas was argon and the collision energy was 17-22 eV. Quantification was done by monitoring the mass transitions of m/z 174→133, m/z 188→105, and m/z 228→159 for bicifadine, M12, and the IS, respectively. The peak area ratios of bicifadine/IS, M12/IS, and the theoretical concentrations of the calibration standards were fit to a quadratic function with 1/x 2 weighting, excluding the origin. The assay range for bicifadine in mouse, rat, and monkey plasma was 4.13 to 1652 ng/ml and 5 to 2000 ng/ml for M12.
Metabolite Profiling and Identification. Pooled plasma samples collected 1 and 4 h postdose were extracted twice with 3 volumes of acetonitrile and centrifuged. The extracts were combined, evaporated to dryness under a stream of nitrogen, and resuspended in the reconstitution fluid (water:acetonitrile, 1:1).
Urine samples from the 0-24 h mouse and rat and 0-48 h monkey collections were pooled such that the pools constituted a fixed percent of the volume from each sample (10% mouse and rat; 5% monkey). The urine was centrifuged in a filtration device (Millipore 0.5 ml Ultrafree-MC 0.45 µm; Billerica, MA) and used for metabolite profiling without further processing. Ten percent of each fecal sample homogenate was pooled to form a single pool for each group (0-48 h for mice and rats; 0-72 h for monkeys). Samples were extracted twice with approximately 3 volumes of acetonitrile and centrifuged. The supernatants were combined, evaporated to dryness under a stream of nitrogen, and resuspended.
Ten percent of each rat bile sample from the 0-24 h collection period was pooled, according to sex, clarified using a centrifugal filtration device, and profiled without software (Waters Corporation). The mobile phase solvents used in the gradient elution were 0.10% formic acid in reverse osmosis water and acetonitrile; the flow rate was 1.0 ml/min. Ultima-Flow M LSC cocktail was used as the scintillant (2.1 ml/min). After passing through the column, 30% of the flow was diverted to the mass spectrometer and 70% to the radiometric detector. The mass spectrometer was used in the electrospray positive mode with cone voltage of 10 to 28 volts. The mass range was 100 to 660 amu with a scan time of 0 to 55 min.
The source block temperature was 130ºC and the desolvation temperature was 325ºC. The ESI nebulizer and bath gas was N 2 (15 l/h and 425 l/h, respectively).
This article has not been copyedited and formatted. The final version may differ from this version. (Table 3 ). Both C max and AUC 0-∞ for radioactivity and bicifadine were approximately 2-4 times higher in rats compared to mice. The higher plasma concentrations of the parent drug were due to a smaller V z and CL in the rat compared to the mouse. The absolute bioavailability of bicifadine was 50-63% in the mouse and approximately 79-85% in the rat. In the monkey, C max values of plasma radioactivity and bicifadine were 6200 ng equiv/g and 1300 ng/ml, respectively, after an oral dose of 8 mg/kg. The compound's CL and F in the monkey were the lowest of the 3 species. Bicifadine and its metabolites were not concentrated in red blood cells since the concentration of radioactivity in whole ]bicifadine was unbound in mouse plasma at concentrations of 100 to 1000 ng/ml, increasing to 20% when the concentration was increased to 10,000 ng/ml (Table 4 ). In both the rat and monkey, only 4-5% was unbound over the concentration range of 100 to 10,000 ng/ml. In comparison, 2.2% to 2.6% of [ 14 C]bicifadine was unbound in human plasma over the concentration range of 100 to 3000 ng/ml.
Excretion of Radioactivity.
By 168 h postdose, 63-72% of the oral dose of radioactivity to mice was in urine while 13-24% was in the feces (Table 5 ). The cage washes and wipes contained another 9%. At the end of the collection period, 0.3% or less of the dose remained in the mouse carcass. Total recovery was 96% and 93% in male and female mice, respectively. In rats, 57-61% was recovered in the urine while another 34-36% was in the feces.
This article has not been copyedited and formatted. The final version may differ from this version. absorbed and fecal radioactivity in intact rats was due to biliary excretion. Only 0.4-0.5% of the radioactivity remained in the carcass at 72 h postdose; total recovery was ≥99%. In monkeys, 57% of the orally-administered radioactivity was in the urine of the males and 33% was in the urine of the females. Only 7%
was in the feces of either sex. A larger percentage of the radioactivity was recovered in the cage washes and wipes, which could be due to either urinary or fecal excretion. Total recovery in the monkeys was approximately 91%. In all 3 species, most of the radioactivity was excreted by 48 h postdose and the pattern of excretion after the i.v. dose was similar to the oral dose (data not shown).
Metabolite Profiling. Representative metabolite profiles in the plasma and urine of mice, rats, and monkeys are illustrated in Figures 3 and 4 , respectively. The proposed metabolic pathway of bicifadine in mouse, rat, and monkey is presented in Figure 5 . The plasma concentrations of the metabolites are presented in Table 6 . The percentage of the dose in the urine and feces associated with the metabolites were calculated similarly, but using the percent of the radioactivity excreted by 24, 48, or 72 h, depending on the species and matrix (Table 7) .
Mouse Plasma. The major metabolites in male and female mice 1 h after the oral dose of [ , 1982; Janssen et al., 1982) . M19 eluted approximately 1 min before M9 and had a protonated molecular ion and product mass spectrum that were similar to M9.
The position of oxidation, though, was at C4 of the pyrrolidine ring rather than at C2. Mouse plasma also contained several minor metabolites that eluted at approximately 44 min and 51 min; their structures were not identified. At 4 h postdose, M9 and M12 were the two predominant metabolites in mouse plasma.
The metabolite profiles in mice 1 h after the i.v. dose were similar to the oral profiles; the plasma radioactivity, though, was predominantly associated only with M12 at 4 h (data not shown).
Rat Plasma. At 1 h after the oral dose, the two most prominent peaks in plasma were M12 and bicifadine in both male and female rats. The concentrations of M3 and M9 were similar to those in mice but represented a smaller percentage of the radiochemical profile due to the higher concentration of total drug equivalents.
Plasma from female rats also contained an N-sulfate conjugate of bicifadine (M23). There were minor amounts of two unidentified metabolites (M20 and M21). By 4 h postdose, the plasma radioactivity was associated mainly with M12
This article has not been copyedited and formatted. The final version may differ from this version. Urine. The main urinary metabolite in all 3 species was the lactam acid (M9). In mice and rats, it constituted 36-39% of the dose and was also the major urinary metabolite in monkeys (Table 7) . Mouse urine contained lesser amounts M27, Bile. The carboxylic acid metabolite M3 in rat bile accounted for 10.7% of the orally administered dose in male rats and 5.6% in female rats; its acyl glucuronide conjugate represented another 12.5-12.6% of the dose (Table 7) .
The other acid-containing metabolite, M9, was also present in the bile sample (Table 9 ). In addition, they had the same HPLC retention times as the authentic standards. to the carboxylic acid while the ion at m/z 218 showed that an acetyl group was present. It could not be determined in these studies whether the acetyl group was added before or after lactam formation. C2 atom in the in vitro-generated metabolite had m/z ratios that were increased by 2 amu when compared to M10 formed in vivo using bicifadine labeled at a much lower specific activity. The rest of the proposed fragments, which did not contain the C2 atom, had the same m/z ratios between the two spectra.
M2 (hydroxymethyl bicifadine
)
M5 (N-acetyl M9

M10 (hydroxy bicifadine). M10 had a [M + H]
M14A-F (M3 acyl glucuronides).
A series of peaks eluted between 6.8 and 9 min, all of which had a full scan [M + H] + at m/z 389, 176 amu (glucuronic acid) higher than M3. The ion at m/z 204 was due to the loss of the glucuronic acid moiety, which was the base peak in the product mass spectrum for some of the glucuronides.
This article has not been copyedited and formatted. The final version may differ from this version. 
M17 (pyrrolidine ring-opened bicifadine). M17 had a full spectrum [M + H] + at
m/z 206, 32 amu (2 oxygen atoms) higher than bicifadine. The ions at m/z 105 and 91 indicated that hydroxylation had not occurred on the methyl group. The loss of water, CO, and formic acid from the m/z 189 fragment ion indicated that a terminal carboxylic acid was present. The addition of water across the C1 and C2 position of the pyrridoline ring of bicifadine could result in a ring-opened metabolite containing both a terminal amine and carboxylic groups.
M19 (C4 lactam acid). The full spectrum [M + H]
+ of M19 was at m/z 218, the same molecular weight as M9. The ion at m/z 135 indicated that the methyl group was oxidized to the carboxylic acid. The differences in the way that M19
fragmented with respect to M9, though, demonstrated that oxidation had occurred at the C4 position on the pyrrolidine ring.
M23 (bicifadine N-sulfate). The full spectrum [M + H]
+ of M23 was 80 amu (sulfate) higher than bicifadine. The product ion mass spectrum of the acetonitrile adduct of M23 (m/z 295) gave ions that included m/z 174 (-sulfate) and three ions that were similar to those in bicifadine (m/z 157, 142, and 105).
M24 (bicifadine C4 lactam). The full spectrum [M + H] + of this metabolite was at
m/z 188, 14 amu (oxygen -2 hydrogen) higher than that of bicifadine. The ion at m/z 105 indicated that the methyl group was not modified. The differences in the fragmentation of M24 with respect to M12 indicated that the oxidation had occurred on the C4 position of the pyrrolidine ring. its product ion mass spectrum gave an ion at m/z 200, indicating the loss of the taurine moiety.
M25 (M9 taurine conjugate
M27 (M3 taurine conjugate). The [M + H]
+ of M27 was 107 amu higher than that of M3 and its base peak (m/z 186) corresponded to the loss of the taurine moiety.
M29A-B. The [M + H]
+ of both M29A and M29B was at m/z 436, 262 amu higher than bicifadine. Their product ion mass spectra were similar with minor differences. They were detected only in mouse plasma; a structure has not been proposed for either metabolite. 
M31A-F (M9 acyl glucuronides
DISCUSSION
The oral bioavailability of bicifadine was high in mice (50-63%) and rats (79-85%), indicating that first pass metabolism of the compound was low. In monkeys, bioavailability was slightly lower (33-42%). Plasma clearance after the IV dose, though, was either similar or higher than can be accounted for only by Elimination of drug-related radioactivity was mainly via the urine.
Radioactivity in the feces of intact rats was due predominantly to biliary excretion.
Only 3% of the orally-administered radioactivity was recovered in the feces from BDC rats, showing that essentially all of the orally administered [ the urine, the metabolites in rat bile were either carboxylic acids or their conjugates with no detectable concentrations of the unchanged parent or M9.
M9 is formed by oxidation of both the ring C2 carbon and the methyl group. Experiments using mouse and monkey hepatocytes suggested that the lactam is formed first, followed by oxidation of the methyl group (Erickson et al., 2007) . The concentration of M12 was higher at 1 h of incubation and then declined at 4 h, indicating a precursor-product relationship between M12 and M9.
In contrast, there was a time-dependent increase in the concentration of M3 from 1 h to 4 h of incubation.
Multiple peaks with the appropriate molecular weight and fragmentation for acyl glucuronides of M3 were observed in the plasma of mice after both i.v.
and oral dosing and in plasma from i.v.-dosed, but not orally-dosed, monkeys (Figure 3 ). They were also detected in urine from all 3 species and in rat bile.
Acyl-substituted glucuronides of M9 were in urine from monkeys but not from mice and rats. Rearrangement of the initial β-O-acyl glucuronides to other isomers is a well-established phenomenon, such as glucuronide conjugates of bilirubin-IX alpha (Compernolle et al, 1978) , zomepirac (Hasegawa et al., 1982) , and 3-(p-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid (Janssen et al, 1982 ).
In conclusion, bicifadine was readily absorbed by the mouse, rat, and monkey. Most of the drug-derived plasma radioactivity was associated with metabolites in the 3 species. Bicifadine readily penetrated into to the rat brain.
Clearance was due to metabolism with the formation of the lactam and oxidation This article has not been copyedited and formatted. The final version may differ from this version. All profiles are from pooled plasma collected 1 h after dosing. Table 1 Pharmacokinetics of Radioactivity, Bicifadine, and M12 in Mice Following Oral (20 mg/kg) Table 2 Pharmacokinetics of Radioactivity, Bicifadine, and M12 in Rats Following Oral (20 mg/kg) This article has not been copyedited and formatted. The final version may differ from this version.
